Beta
ManageSearchChatDiscover
9841

Clinical Significance of Lymphoid Enhancer-Binding Factor 1 (LEF-1) Expression in Acute Myeloid Leukemia

Article

Last updated: 24 Dec 2024

OverviewSimilar Items

Subjects

-

Tags

-

Abstract

Background: Lymphoid enhancer-binding factor-1 (LEF1) is a member of the LEF/T-cell factor family of transcription factors and a key mediator of the Wingless-type (Wnt) pathway. It mediates Wnt signals through recruiting β-catenin and its co-activators to Wnt response elements of target genes. It plays crucial roles in normal hematopoiesis, not only in the development of B and T lymphocytes but also in granulopoiesis. Objectives: The aim of this study was to evaluate of LEF1 expression levels in patients with AML and correlate this expression with clinical data.
Methodology: The present study was conducted on 30 de novo adult AML patients and 10 age and sex-matched controls with non-malignant hematological disorders (e.g.: hypersplenism, megaloblastic anemia, immune thrombocytopenic purpura) who attended Hematology/Oncology unit of Ain-Shams University Hospitals during the period from May 2017 till January 2018, after taking the approval of the Scientific and Ethical Committee of Ain- Shams University. LEF1 expression levels were measured by quantitative real-time PCR.
Results: The present study showed that there was highly statistically significant association between patients and control group in LEF1 expression level. There was positive significant correlation between LEF1 expression level and Hb level and PLT count. While negative significant correlation was found with age, TLC count and peripheral blood blast %. No correlation was found with bone marrow blasts %. There was statistically significant difference between LEF1 expression level and both hepatosplenomegaly. No statistically significant difference was found between LEF1 expression level and Sex or lymphadenopathy. Conclusion: Our study has shown that Lymphoid Enhancer-Binding Factor 1 (LEF-1) is over expressed in AML patients. LEF1 expression might be involved in the process of disease progression, and possibly can serve as a molecular parameter for risk assessment and/or monitoring of treatment in AML patients. Thus, molecular assessment of LEF1 expression at diagnosis may be of value to add to the prognostic work of AML patients.

DOI

10.21608/ejhm.2018.9841

Keywords

LEF1, Wnt, AML

Authors

First Name

Nahela Ahmed

Last Name

Shalaby

MiddleName

-

Affiliation

Department of Clinical Pathology Faculty of Medicine, Ain Shams University, Cairo, Egypt

Email

-

City

-

Orcid

-

First Name

Doaa Ahmed Gamal

Last Name

Eissa

MiddleName

-

Affiliation

Department of Clinical Pathology Faculty of Medicine, Ain Shams University, Cairo, Egypt

Email

-

City

-

Orcid

-

First Name

Botheina Ahmed Thabet

Last Name

Farweez

MiddleName

-

Affiliation

Department of Clinical Pathology Faculty of Medicine, Ain Shams University, Cairo, Egypt

Email

-

City

-

Orcid

-

First Name

Shaimaa Abdelmalik

Last Name

Pessar

MiddleName

-

Affiliation

Department of Clinical Pathology Faculty of Medicine, Ain Shams University, Cairo, Egypt

Email

-

City

-

Orcid

-

First Name

Raghda El Sayed Abdel Monem

Last Name

Galal

MiddleName

-

Affiliation

Department of Clinical Pathology Faculty of Medicine, Ain Shams University, Cairo, Egypt

Email

-

City

-

Orcid

-

Volume

72

Article Issue

6

Related Issue

1884

Issue Date

2018-07-01

Receive Date

2018-07-28

Publish Date

2018-07-01

Page Start

4,686

Page End

4,692

Print ISSN

1687-2002

Online ISSN

2090-7125

Article File

EJHM_Volume 72_Issue 6_Pages 4686-4692.pdf

PDF . 442.9kB

Link

https://ejhm.journals.ekb.eg/article_9841.html

Detail API

https://ejhm.journals.ekb.eg/service?article_code=9841

Order

18

Type

Original Article

Type Code

606

Publication Type

Journal

Publication Title

The Egyptian Journal of Hospital Medicine

Publication Link

https://ejhm.journals.ekb.eg/

MainTitle

Clinical Significance of Lymphoid Enhancer-Binding Factor 1 (LEF-1) Expression in Acute Myeloid Leukemia

Details

Type

Article

Created At

22 Jan 2023